自身抗体浓度及其轨迹与狼疮肾炎组织学特征和治疗应答的关联
在加速药物伙伴关系狼疮肾炎纵向队列的279例系统性红斑狼疮患者中,于肾活检时及活检后3、6、12个月检测13种自身抗体。增殖性狼疮肾炎与抗C1q、抗染色质、抗双链DNA和抗核糖体P抗体浓度较高相关,基線抗C1q水平可预测完全应答。
要点
- 增殖性狼疮肾炎(ISN/RPS III/IV±V型)与抗C1q、抗染色质、抗dsDNA和抗核糖体P抗体浓度较高相关。
- 抗C1q和抗dsDNA独立与增殖性狼疮肾炎相关。
- 增殖性狼疮肾炎中,基线抗C1q水平预测完全应答的AUC为0.72(P=0.002),优于基线蛋白尿的AUC 0.59(P=0.21)。
核心结论
- 基线抗C1q和抗dsDNA水平可能作为增殖性狼疮肾炎的无创生物标志物,抗C1q可能在肾活检时预测完全应答。
- 纵向追踪自身抗体可能为了解增殖性狼疮肾炎患者的治疗应答和致病机制提供进一步见解。
研究设计与样本
- 研究纳入加速药物伙伴关系狼疮肾炎纵向队列中279例因蛋白尿接受诊断性肾活检的系统性红斑狼疮患者,其中268例诊断为狼疮肾炎。
- 采用基于珠的检测法(Bio-Rad Bioplex 2200)测定13种自身抗体特异性,并以酶联免疫吸附试验测定抗C1q,检测时间点为肾活检时(基线)及活检后3、6、12个月。
- 临床应答在12个月时判定。
主要发现
- 增殖性狼疮肾炎(ISN/RPS III/IV±V型,n=160)较非增殖性狼疮肾炎(I/II/V/VI型,n=108)与更高浓度的抗C1q、抗染色质、抗双链DNA(dsDNA)和抗核糖体P自身抗体相关。
- 抗C1q和抗dsDNA独立与增殖性狼疮肾炎相关。
- 在增殖性狼疮肾炎中,较高基线抗C1q水平预测完全应答(AUC 0.72;P=0.002),优于基线蛋白尿(AUC 0.59;P=0.21)。
- 在达到完全应答的增殖性狼疮肾炎(而非膜性狼疮肾炎)患者中,除抗La/SSB外所有自身抗体水平在12个月内下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response are not adequately known. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership LN longitudinal cohort to identify serological biomarkers of LN histologic classification and treatment response and how these biomarkers change over time based on treatment response. METHODS: Peripheral blood samples were collected from 279 patients with systemic lupus erythematosus undergoing diagnostic kidney biopsy based on proteinuria. Of these, 268 were diagnosed with LN. Thirteen autoantibody specificities were measured by bead-based assays (Bio-Rad Bioplex 2200) and anti-C1q by enzyme-linked immunosorbent assay at the time of biopsy (baseline) and at 3, 6, and 12 months after biopsy. Clinical response was determined at 12 months. RESULTS: Proliferative LN (International Society of Nephrology/Renal Pathology Society class III/IV±V, n = 160) was associated with higher concentrations of anti-C1q, anti-chromatin, anti-double-stranded DNA (dsDNA), and anti-ribosomal P autoantibodies compared to nonproliferative LN (classes I/II/V/VI, n = 108). Anti-C1q and-dsDNA were independently associated with proliferative LN. In proliferative LN, higher baseline anti-C1q levels predicted complete response (area under the curve [AUC] 0.72; P = 0.002) better than baseline proteinuria (AUC 0.59; P = 0.21). Furthermore, all autoantibody levels except for anti-La/SSB decreased over 12 months in patients with proliferative, but not membranous, LN with a complete response. CONCLUSION: Baseline levels of anti-C1q and anti-dsDNA may serve as noninvasive biomarkers of proliferative LN, and anti-C1q may predict complete response at the time of kidney biopsy. In addition, tracking autoantibodies over time may provide further insights into treatment response and pathogenic mechanisms in patients with proliferative LN.
引用
- Fava A, Wagner CA, Guthridge CJ, et al. Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response. Arthritis Rheumatol. 2024. PMID: 38962936. doi:10.1002/art.42941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。